Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CB-280 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | CB-280 twice daily at 50 mg for 14 days |
| Cohort 2 | EXPERIMENTAL | CB-280 twice daily at 100 mg for 14 days |
| Cohort 3 | EXPERIMENTAL | CB-280 twice daily at 200 mg for 14 days |
| Cohort 4 | EXPERIMENTAL | CB-280 twice daily at 400 mg for 14 days |
| Placebo | PLACEBO_COMPARATOR | Placebo twice daily for 14 days |
| Name | Type | Description |
|---|---|---|
| CB-280 | DRUG | CB-280, oral capsule administered twice daily at the assigned dose level for 14 days |
| Placebos | DRUG | Placebo oral capsule administrated twice daily at the assigned dose level for 14 days |
Inclusion Criteria: 1. Written Informed Consent in accordance with federal, local, and institutional guidelines 2. Confirmed diagnosis of cystic fibrosis 3. Male or female subjects ≥ 18 years on the date of informed consent 4. Percent predicted FEV1 of 40-90% at screening per Global Lung Function I...
Top 6 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | Alyftrek, Trikafta, Ivacaftor, VX-581, VX-272 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Roivant Sciences Ltd. | ROIV | 1 | PHASE2 | SP-101 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |